Y-mAbs Therapeutics, Inc.
YMABNext catalyst
Hu3F8 With GM-CSF
Neuroblastoma
Get an email about YMAB's next catalysts
Track Y-mAbs Therapeutics (YMAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
Hu3F8 With GM-CSF Phase 2 Est. Readout
Estimated primary completion for Hu3F8 With GM-CSF trial (NCT01757626) in Neuroblastoma. Topline data typically follows completion by weeks to months.
Sourcehumanized anti-GD2 antibody Phase 2 Est. Readout
Estimated primary completion for humanized anti-GD2 antibody trial (NCT02502786) in Recurrent Osteosarcoma. Topline data typically follows completion by weeks to months.
Source131 I-omburtamab Phase 2 Est. Readout
Estimated primary completion for 131 I-omburtamab trial (NCT04022213) in Desmoplastic Small Round Cell Tumor. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
GM-CSF + Naxitamab
Neuroblastoma
Hu3F8 With GM-CSF
Neuroblastoma
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
Neuroblastoma
Hu3F8
Neuroblastoma
Naxitamab
Neuroblastoma
131 I-omburtamab
Desmoplastic Small Round Cell Tumor
humanized anti-GD2 antibody
Recurrent Osteosarcoma
Omburtamab I-131
Recurrent Medulloblastoma
Antipyretic
Recurrent Medulloblastoma
SSKI
Recurrent Medulloblastoma
anti-emetics
Recurrent Medulloblastoma
oral β-glucan
Neuroblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GM-CSF + Naxitamab | Phase 2 | Neuroblastoma | - | - |
Hu3F8 With GM-CSF | Phase 2 | Neuroblastoma | - | - |
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | Phase 2 | Neuroblastoma | - | - |
Hu3F8 | Phase 2 | Neuroblastoma | - | - |
Naxitamab | Phase 2 | Neuroblastoma | - | - |
131 I-omburtamab | Phase 2 | Desmoplastic Small Round Cell Tumor | - | - |
humanized anti-GD2 antibody | Phase 2 | Recurrent Osteosarcoma | - | - |
Omburtamab I-131 | Phase 2 | Recurrent Medulloblastoma | - | - |
Antipyretic | Phase 2 | Recurrent Medulloblastoma | - | - |
SSKI | Phase 2 | Recurrent Medulloblastoma | - | - |
anti-emetics | Phase 2 | Recurrent Medulloblastoma | - | - |
oral β-glucan | Phase 2 | Neuroblastoma | - | - |
Frequently asked questions
What is in Y-mAbs Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Y-mAbs Therapeutics, Inc.'s (YMAB) pipeline across Phase 2. Its lead program is 131 I-omburtamab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Y-mAbs Therapeutics, Inc.'s next FDA catalyst?→
Y-mAbs Therapeutics, Inc.'s (YMAB) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track YMAB biotech catalysts?→
Add YMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Y-mAbs Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
